Search Results
28 protocol(s) meet the specified criteria
Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial Testing Ipatasertib plus Abiraterone plus Prednisone/Prednisolone, Relative to Placebo plus Abiraterone plus Prednisone/Prednisolone in Adult Male Patients with Asymptomatic or Mildly Symptomatic, Previously Untreated, Metastatic Castrate-Resistant Prostate Cancer

Phase II Open-Label Single-Arm Study of Adjuvant Nivolumab following Chemo-Radiation in localized Muscle-Invasive Bladder Cancer (NEXT)

101274Not Open *
Phase I Study Evaluating the Safety, Pharmacokinetics and Anti-Tumor Activity of ABBV-176 in Subjects with Advanced Solid Tumors likely to Express Prolactin Receptor (PRLR)

Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

PCCTC c16-168: BRCAAway: Randomized Phase II Trial of Abiraterone, Olaparib, or Abiraterone plus Olaparib in Patients with Metastatic Castration-Resistant Prostate Cancer with DNA Repair Defects

Phase IB, Open-Label, Dose-Finding Study to Evaluate the Safety and Tolerability of Cabometyx and Avelumab in Patients with Metastatic Renal Cell Carcinoma (mRCC)

Phase II Study of Radium-223 and Radiotherapy in Hormone-Naïve Men with Oligometastatic Prostate Cancer to Bone

Phase IB Dose-Escalation Study of Cabozantinib Administered in Combination with Atezolizumab to Subjects with Locally Advanced or Metastatic Solid Tumors

Phase I/II, Open-Label, Dose-Finding, Proof of Concept, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of CX-2009 in Adults with Metastatic or Locally Advanced Unresectable Solid Tumors

Randomized Phase III Trial of Hypofractionated Post-Prostatectomy Radiation Therapy (Hyport) versus Conventional Post-Prostatectomy Radiation Therapy (Coport)

Nonpharmacologic Interventions for Fatigue in Patients with Cancer

Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Talazoparib in Combination with Physician's Choice of Enzalutamide or Abiraterone Acetate/Prednisone in Metastatic Castration-Resistant Prostate Cancer with DNA Damage Repair Deficiencies

Phase I/II Open Label Study of the Safety and Efficacy of Apatinib Administered to Patients with Advanced Malignancies to Improve Sensitivity to Pembrolizumab in the Second- or Later-Line Setting (APPEASE)

Randomized, Double-Blind, Placebo-Controlled Phase II Study Comparing CB-839 in Combination with Cabozantinib (CB-Cabo) versus Placebo with Cabozantinib (Pbo-Cabo) in Patients with Advanced or Metastatic Renal Cell Carcinoma (RCC)

Cabazitaxel with Abiraterone versus Abiraterone alone Randomized Trial for Extensive Disease following Docetaxel: CHAARTED2 Trial

Phase I/IB Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies

Phase I/IIA Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors

Phase I/II, Open-Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination with PDR001 Administered to Patients with Advanced Malignancies

Randomized, Double-Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First-Line Chemotherapy in Patients with Metastatic Urothelial Cancer

Phase II Trial of Pembrolizumab in Subjects with Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-199)

Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib, Crizotinib, Savolitinib, and Sunitinib) in Metastatic Papillary Renal Carcinoma (PAPMET)

Phase II, Open-Label, Single-Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects with Metastatic or Surgically Unresectable Urothelial Carcinoma Harboring FGF/FGFR Alterations

Phase III, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy in Patients with Renal Cell Carcinoma at High Risk of Developing Metastasis Following Nephrectomy

Single-Arm, Multicenter, Phase II Trial to Evaluate Efficacy and Safety of Lenvatinib in Combination with Everolimus in Subjects with Unresectable Advanced or Metastatic Non-Clear-Cell Renal Cell Carcinoma (nccRCC) who have not Received any Chemotherapy for Advanced Disease

Phase II Study of Brentuximab Vedotin and Bevacizumab in Refractory CD-30 Positive Germ Cell Tumors

Phase III, Open Label, Randomized Study to Assess the Efficacy and Safety of Olaparib (Lynparza) versus Enzalutamide or Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer Who Have Failed Prior Treatment with a New Hormonal Agent and have Homologous Recombination Repair Gene Mutations (PROfound)

Open-Label Phase I/IIA Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients with Metastatic Castration-Resistant Prostate Cancer

Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG before Intravesical Therapy for BCG-Naïve High-Grade Non-Muscle Invasive Bladder Cancer